Perelló Bratescu, AinaDürsteler, ChristianÁlvarez- Carrera, Maria AsunciónGranés, LauraKostov, BelchinSisó Almirall, Antoni2023-08-022023-08-022022-01-311660-4601https://hdl.handle.net/2445/201468The prescription of strong opioids (SO) for chronic non-cancer pain (CNCP) is steadily increasing. This entails a high risk of adverse effects, a risk that increases with the concomitant prescription of SO with central nervous system depressant drugs and with the use of SO for non-recommended indications. In order to examine this concomitant risk prescription, we designed a descriptive, longitudinal, retrospective population-based study. Patients aged >= 15 years with a continued SO prescription for >= 3 months during 2013-2017 for CNCP were included. Of these, patients who had received concomitant prescriptions of SO and risk drugs (gabapentinoids, benzodiazepines and antidepressants) and those who had received immediate-release fentanyl (IRF) were selected. The study included 22,691 patients; 20,354 (89.7%) patients received concomitant risk prescriptions. Men and subjects with a higher socioeconomic status received fewer concomitant risk prescriptions. Benzodiazepines or Z-drugs were prescribed concomitantly with SO in 15,883 (70%) patients, antidepressants in 14,932 (65%) and gabapentinoids in 11,267 (49%), while 483 (21.32%) patients received IRF (2266 prescriptions in total) without a baseline SO. In conclusion, our study shows that a high percentage of patients prescribed SO for CNCP received concomitant prescriptions with known risks, as well as IRF for unauthorized indications.10 p.application/pdfengcc by (c) Perelló Bratescu, Aina et al., 2022http://creativecommons.org/licenses/by/3.0/es/Tractament del dolorAvaluació del risc per la salutOpiacisPain treatmentHealth risk assessmentOpioidsinfo:eu-repo/semantics/article2023-07-04info:eu-repo/semantics/openAccess929848835162674